The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

American Society of Clinical Psychopharmacology
May 27th – 30th 2025, Scottsdale, AZ
Explore materials from this congress
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted. Audio abstracts are generated using text-to-speech software and contain an audio version of the abstract that was submitted and accepted as part of the official conference materials.
Bipolar Disorder
Schizophrenia
POSTER
Lipid and Glycemic Profile of Olanzapine and Samidorphan: A Patient Subgroup Analysis of a 4-Year Open-Label Study
AUTHOR(S)

Jacob S. Ballon, MD, MPH,1 Christina Arevalo, MS,2 Martin Dunbar, PhD,2 Alexandra Lovett, MD,2 Christoph U. Correll, MD3-6

Embargo date: 05-29-2025 Embargo time: 11:30 MDT
Bipolar Disorder
Schizophrenia
Schizophrenia
ENCORE POSTER
Acute and Maintenance Treatment Effects of Olanzapine/Samidorphan on Negative Symptoms in Patients with Schizophrenia: A Post Hoc Analysis
AUTHOR(S)

Roger S. McIntyre,1 Desiree M. Matthews,2 Marni E. Harris,3 Christina Arevalo,3 Martin Dunbar,3 David McDonnell,4 Christoph U. Correll5-7

Embargo date: 05-29-2025 Embargo time: 11:30 MDT
Schizophrenia
Bipolar Disorder
ENCORE POSTER
Healthcare Resource Utilization 12 Months following Initiation of Olanzapine/Samidorphan: Real-World Assessment of Patients with Bipolar I Disorder
AUTHOR(S)

Rakesh Jain, MD, MPH,1 Hemangi R. Panchmatia, MSc,2 Alejandro G. Hughes, MPH,3 Michael J. Doane, PhD,2 Hara E. Oyedeji, CRNP, MS,4 Andrew J. Cutler, MD5,6

Embargo date: 05-29-2025 Embargo time: 11:30 MDT
Bipolar Disorder
Schizophrenia
ENCORE POSTER
Healthcare Resource Utilization 12 Months following Initiation of Olanzapine/Samidorphan: Real-World Assessment of Patients with Schizophrenia
AUTHOR(S)

Andrew J. Cutler, MD,1,2 Hemangi R. Panchmatia, MSc,3 Alejandro G. Hughes, MPH,4 Michael J. Doane, PhD,3 Hara E. Oyedeji, CRNP, MS,5 Rakesh Jain, MD, MPH6

Embargo date: 05-29-2025 Embargo time: 11:30 MDT
Schizophrenia
Schizophrenia
ENCORE POSTER
Baseline Severity of Illness and Response to Treatment with Aripiprazole Lauroxil Every 2 Months: A Post Hoc Analysis of Phase 3 ALPINE Clinical Trial Data
AUTHOR(S)

John M. Kane, MD1 ; Martin Dunbar, PhD2 ; and James A. McGrory, PhD2

Embargo date: 05-29-2025 Embargo time: 11:30 MDT
Schizophrenia
Bipolar Disorder
Schizophrenia
ENCORE POSTER
Safety, Tolerability, and Durability of Treatment Effect of Olanzapine and Samidorphan: A Patient Subgroup Analysis of a 4-Year Open-Label Study
AUTHOR(S)

Jacob S. Ballon, MD, MPH,1 Christina Arevalo, MS,2 Martin Dunbar, PhD,2 Alexandra Lovett, MD,2 David McDonnell, MD,3 Christoph U. Correll, MD4-7

Embargo date: 05-29-2025 Embargo time: 11:30 MDT
Bipolar Disorder
Schizophrenia
Bipolar Disorder
Schizophrenia
ENCORE POSTER
Study Retention Rates in the Olanzapine/Samidorphan Phase 3 Clinical Program
AUTHOR(S)

René S. Kahn,1 Christina Arevalo,2 Marni E. Harris,2 David McDonnell3 

Embargo date: 05-29-2025 Embargo time: 11:30 MDT
Bipolar Disorder
Schizophrenia